166 related articles for article (PubMed ID: 36828828)
21. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
Eveillard M; Rustad E; Roshal M; Zhang Y; Ciardiello A; Korde N; Hultcrantz M; Lu S; Shah U; Hassoun H; Smith E; Lesokhin A; Mailankody S; Landgren O; Thoren K
Br J Haematol; 2020 Jun; 189(5):904-907. PubMed ID: 32026474
[TBL] [Abstract][Full Text] [Related]
22. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
[No Abstract] [Full Text] [Related]
23. Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma.
Olteanu H
Surg Pathol Clin; 2016 Mar; 9(1):101-16. PubMed ID: 26940271
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice.
Owen RG; Rawstron AC
Br J Haematol; 2005 Mar; 128(5):732-3; author reply 733-4. PubMed ID: 15725097
[No Abstract] [Full Text] [Related]
25. Minimal residual disease detection in myeloma: no more molecular remissions?
Rawstron AC
Haematologica; 2005 Oct; 90(10):1300B. PubMed ID: 16219557
[No Abstract] [Full Text] [Related]
26. Minimal residual disease in multiple myeloma: why, when, where.
Yee AJ; Raje N
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):37-45. PubMed ID: 34889430
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].
Nihon Rinsho; 2016 Jul; 74 Suppl 5():557-60. PubMed ID: 30708407
[No Abstract] [Full Text] [Related]
28. Flow cytometric myeloma measurable residual disease testing in the era of targeted therapies.
Ng DP
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():71-77. PubMed ID: 34288444
[TBL] [Abstract][Full Text] [Related]
29. [Detection of minimal residual disease in leukemia using flow cytometry].
Muroi K
Rinsho Ketsueki; 2008 Jun; 49(6):397-407. PubMed ID: 18646607
[No Abstract] [Full Text] [Related]
30. Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods.
Yoroidaka T; Narita K; Takamatsu H; Fujisawa M; Nakao S; Matsue K
Sci Rep; 2021 May; 11(1):11218. PubMed ID: 34045494
[TBL] [Abstract][Full Text] [Related]
31. Assessment of response to therapy in multiple myeloma by multiparameter flow cytometry. Usefulness of an eight-color single tube with monoclonal antibodies in dried formulation.
Carulli G; Tarasco A; Sammuri P; Ottaviano V; Domenichini C; Ciancia EM; Petrini M
Clin Ter; 2019; 170(5):e352-e356. PubMed ID: 31612192
[TBL] [Abstract][Full Text] [Related]
32. Immunophenotyping by Mass Cytometry.
Behbehani GK
Methods Mol Biol; 2019; 2032():31-51. PubMed ID: 31522411
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
Sato K; Okazuka K; Ishida T; Sakamoto J; Kaneko S; Nashimoto J; Uto Y; Ogura M; Yoshiki Y; Abe Y; Maeda A; Hamazaki H; Tsukada N; Hiragohri Y; Suzuki K
Ann Hematol; 2021 Dec; 100(12):2989-2995. PubMed ID: 34430990
[TBL] [Abstract][Full Text] [Related]
34. [Research progress on multiple myeloma immunophenotyping and minimal residual disease detected by flow cytometry].
Li HQ; Zhai YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):241-5. PubMed ID: 25687080
[TBL] [Abstract][Full Text] [Related]
35. Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies.
Zajec M; Jacobs JFM; Groenen PJTA; de Kat Angelino CM; Stingl C; Luider TM; De Rijke YB; VanDuijn MM
J Proteome Res; 2018 Mar; 17(3):1326-1333. PubMed ID: 29424538
[TBL] [Abstract][Full Text] [Related]
36. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.
Rawstron AC; Gregory WM; de Tute RM; Davies FE; Bell SE; Drayson MT; Cook G; Jackson GH; Morgan GJ; Child JA; Owen RG
Blood; 2015 Mar; 125(12):1932-5. PubMed ID: 25645353
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications.
Soh KT; Wallace PK
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():43-53. PubMed ID: 34288449
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.
Landgren O; Gormley N; Turley D; Owen RG; Rawstron A; Paiva B; Barnett D; Arroz M; Wallace P; Durie B; Yuan C; Dogan A; Stetler-Stevenson M; Marti GE
Am J Hematol; 2014 Dec; 89(12):1159-60. PubMed ID: 25132630
[No Abstract] [Full Text] [Related]
40. Detection of minimal residual disease.
Deptala A; Mayer SP
Methods Cell Biol; 2001; 64():385-420. PubMed ID: 11070849
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
